HCPCS code J7676 – Pentamidine isethionate

Key takeaways

HCPCS Code J7676 covers compounded pentamidine isethionate inhalation solution, per 300 mg unit dose, delivered through a DME nebulizer.

J2545 covers the FDA-approved non-compounded version of the same drug, so the pharmacy’s product decides which code you file.

Medicare Part B covers J7676 under the DMEPOS fee schedule, at rates that vary by locality and change every January.

A signed physician order and a diagnosis supporting PCP risk carry medical necessity, since CMS retired the Certificate of Medical Necessity in 2023.

Pabau’s claims management software supports HCPCS Level II J code entry, claim generation, and documentation tracking for compounded inhalation drugs.

HCPCS Code J7676: definition and code attributes

HCPCS Code J7676 describes pentamidine isethionate, inhalation solution, compounded product, administered through DME, unit dose form, per 300 mg. It sits within the HCPCS Level II J-code range, which CMS maintains annually as the classification system for drugs and biologicals not covered by CPT. The short descriptor used on claims is “Pentamidine comp unit dose.”

The key word here is compounded. J7676 applies only to pharmacy-compounded pentamidine prepared specifically for inhalation. The nebulizer is the delivery device, classified as DME, which places this code in the DME billing pathway rather than the physician drug-administration pathway.

When pentamidine inhalation is prescribed

Pentamidine inhalation is used primarily for Pneumocystis jirovecii pneumonia (PCP) prophylaxis in immunocompromised patients. The standard prophylaxis regimen is 300 mg through a nebulizer once every four weeks, which maps directly to J7676’s unit-of-service definition.

The patient population includes adults with HIV/AIDS, solid organ transplant recipients on immunosuppressant therapy, and patients with hematologic malignancies receiving chemotherapy. Pentamidine inhalation is typically prescribed when first-line PCP prophylaxis with trimethoprim-sulfamethoxazole is contraindicated or not tolerated.

• HIV/AIDS (B20): PCP prophylaxis indicated when CD4 count falls below 200 cells/mm³
• Post-transplant immunosuppression (Z94.x): Used when TMP-SMX allergy or intolerance is documented
• Hematologic malignancy (C81-C96): During or after intensive chemotherapy regimens
• Primary immunodeficiency (D84.9): Other documented immunodeficient states with PCP risk
• Bone marrow transplant (Z94.81): Standard prophylaxis protocol during engraftment period

The clinical indication drives coding accuracy. The ICD-10 diagnosis code submitted with J7676 must substantiate medical necessity. A claim filed with an unrelated or insufficiently specific diagnosis is a common denial trigger.

J7676 billing guidelines

J7676 is billed by the DME supplier, not the prescribing physician. This is the billing detail that trips up practices most often. The physician writes the order and documents medical necessity. The licensed DME supplier or pharmacy that prepares and dispenses the compounded solution submits the claim. Practices that also operate as DME suppliers must hold the appropriate DMEPOS supplier number to bill this code.

The unit of service is per 300 mg, so one standard monthly PCP prophylaxis treatment equals one unit. Never report partial units, and never aggregate several months of doses onto a single claim line. Adjudication systems flag units that deviate from expected dispensing patterns.

Before submitting, confirm the pharmacy prepared a compounded solution rather than dispensing the FDA-approved NebuPent brand. Dispensing the branded product and billing J7676 constitutes upcoding. Dispensing a compounded product and billing J2545 is equally incorrect. The compounded versus FDA-approved distinction is the most consequential code-selection decision in pentamidine billing, so record the compound label details on the claim documentation.

Medicare coverage and the DMEPOS fee schedule

Medicare Part B covers J7676 when a qualified DME supplier submits the claim. The claim must also meet the medical necessity criteria set by the relevant Durable Medical Equipment Medicare Administrative Contractor (DME MAC). The diagnosis alone does not guarantee coverage. The documentation package has to show that the patient cannot tolerate first-line prophylaxis, and that the prescribing physician assessed and recorded PCP risk.

Reimbursement is set through the DMEPOS fee schedule, not the Physician Fee Schedule. Rates vary by locality and are updated annually by CMS. Use the DMEPOS fee schedule to confirm the current allowed amount for your MAC jurisdiction before quoting patients on cost-sharing. Amounts change each January, so never cite a dollar figure in patient-facing materials without checking the current year’s file.

Medicare applies the 20% Part B coinsurance after the deductible for most DMEPOS drug claims. Secondary coverage, Medicaid, or supplemental insurance may pick up the remainder. Read the remittance advice line by line, because the remark codes there explain every partial payment. Our guide to denial codes decodes the ones that surface most often on DME drug claims.

ICD-10 diagnosis codes commonly paired with J7676

Every J7676 claim requires a supporting ICD-10-CM diagnosis code that establishes medical necessity for PCP prophylaxis. The diagnosis must reflect the underlying condition creating the immunocompromised state, not the prophylactic treatment itself. CMS and the DME MACs cross-reference submitted diagnosis codes against Local Coverage Determinations (LCDs) to confirm coverage eligibility.

Verify each code against the current CMS ICD-10-CM tabular list before submitting. Codes change annually, so a code valid in a prior year may be retired or may now require additional specificity. Auditing ICD-10 pairing accuracy once a quarter catches those shifts before a payer does.

Modifiers used with J7676

Modifier selection for J7676 depends on the DME billing context and payer requirements. DME suppliers must apply modifiers that identify the type of equipment and the supplier’s role in furnishing it. Missing or incorrect modifiers are among the top reasons DMEPOS claims are returned unprocessable by DME MACs.

Most single-agent J7676 claims use the KO modifier. Confirm modifier requirements with the AAPC HCPCS code reference and verify against the DME MAC’s Local Coverage Article before filing. Payer-specific modifier rules vary, and some commercial plans do not follow Medicare’s modifier logic.

Documentation requirements for J7676

Thorough documentation is the billing team’s primary defense against audits and post-payment recoveries. For J7676, the DME supplier holds the complete documentation package and makes it available on request. Inadequate documentation is a leading cause of J7676 claim recoupment during DME MAC post-payment reviews.

• Physician order / prescription: Written order specifying pentamidine isethionate 300 mg through a nebulizer, the frequency, and the patient name, signed by the treating physician
• No Certificate of Medical Necessity: CMS discontinued CMN and DIF forms for dates of service on or after January 1, 2023. The signed order and the supporting medical records carry the claim instead
• Diagnosis documentation: Progress notes or lab results, such as a CD4 count for HIV patients, confirming the underlying immunocompromised state and PCP risk
• Compounding pharmacy label: Label showing drug name, strength (300 mg), lot number, beyond-use date, and compounding facility details
• Intolerance or contraindication documentation: Clinical notes explaining why first-line trimethoprim-sulfamethoxazole is not appropriate for this patient
• Prior authorization records: Approval documentation where the payer requires prior auth for compounded products, retained after dispensing
• Delivery records: Proof of patient receipt of the drug, including signature where payer policy requires it

Build these requirements into your intake workflow so records are complete before the claim is filed, rather than assembled after a denial arrives. Practices that manage documentation proactively see far fewer post-submission audit findings. Retain every patient record tied to a J7676 claim for the period your state law specifies, which is typically six years at minimum.

J7676 vs J2545: key differences

J2545 covers pentamidine isethionate, inhalation solution, FDA-approved final product, non-compounded, administered through DME. J7676 covers the compounded version of the same drug by the same route. The two codes describe clinically equivalent treatments, and they are billed under entirely different regulatory and coverage frameworks.

Some commercial payers and managed Medicaid plans require the branded product as a condition of coverage, even where the prescribing physician ordered a compounded one. Verify payer-specific coding preferences during prior authorization review. Filing J7676 where the plan requires J2545 produces a denial that no modifier can correct. A fresh claim carrying the right code has to go out instead. The three checks below settle the choice before anything is filed.

Related HCPCS codes and crosswalk

Code selection gets easier once you can see where J7676 sits in the HCPCS inhalation drug family. The codes below share the DME delivery pathway. They differ by drug, by formulation, or by whether the item billed is the drug or the device.

How Pabau supports HCPCS billing for inhalation drugs

Practices that bill HCPCS Level II J codes move faster when code entry, documentation, and claim submission live in one system. Tracking compound dispensing records, modifier selections, and ICD-10 pairings across separate spreadsheets is where DME drug claims come apart. The compound label sits in the pharmacy’s file, the order sits in the chart, and the biller reconstructs both from memory.

Practice management software like Pabau keeps that package together. Its claims management software supports HCPCS Level II J code entry alongside the clinical records that substantiate medical necessity. Teams can attach the physician order, the compound pharmacy label, and the diagnosis documentation to the patient record before the claim goes out. A DME MAC review request then becomes a lookup rather than a scramble.

Practices running PCP prophylaxis programs can use Pabau to track the monthly dispensing cycle and flag patients approaching their next scheduled dose. The supporting ICD-10 codes stay linked to each patient’s active problem list. Recurring J7676 billing then runs off the schedule instead of off whoever remembers it.

Streamline HCPCS billing for compounded drugs

Pabau’s claims management software supports HCPCS Level II J code entry, documentation tracking, and electronic claim submission. Your billing team spends less time chasing denials and more time on patient care.

Book a demo

Conclusion

HCPCS Code J7676 is a narrow code with an expensive failure mode. Get the compounded versus FDA-approved distinction wrong and the claim is headed for denial, whatever else the file contains. Check the plan’s coverage policy and the pharmacy’s actual product before the code is chosen, not after the remittance advice arrives.

The documentation package, the modifier, and the ICD-10 pairing all reward deliberate attention. None of them survive being templated across patients, because each episode turns on its own clinical facts. The practices that bill this code cleanly are the ones that assemble the file first and submit second.

Pabau keeps the order, the compound label and the diagnosis together behind every claim. If your practice bills J7676 or similar HCPCS drug codes, book a demo to see the documentation ride along with the claim.

Continue your research

Need a foundation in HCPCS billing concepts? Medical billing fundamentals covers how HCPCS codes fit into the broader claims lifecycle.

Want to reduce DME claim denials? Denial management in healthcare outlines the workflow for identifying, correcting, and preventing recurring claim rejections.

Preparing for a billing compliance review? Medical billing compliance breaks down audit readiness for outpatient drug and DME claims.

Frequently asked questions